• MDM1, p53, and Chemoradiotherapy Sensitivity in CRC

  2026-09-30

  This 2025 study identifies MDM1 as a functional determinant of colorectal cancer sensitivity to chemoradiotherapy. Its experiments connect MDM1 overexpression with reduced YBX1 binding at the TP53 promoter, increased p53 expression, apoptosis, and improved treatment response, supporting MDM1 as a candidate predictive biomarker.

• 10058-F4 Workflow for c-Myc-Max Studies

  2026-09-29

  Build a mechanism-first workflow around 10058-F4 for c-Myc/Max-dependent transcription, apoptosis, AML differentiation, and TERT regulation. The guide combines practical dosing, chromatin-aware readouts, formulation advice, and troubleshooting for cell-based and translational studies.

• GSK-923295: CENP-E Control of Mitotic Fidelity

  2026-09-29

  GSK-923295 provides a mechanistically defined way to interrogate CENP-E-dependent chromosome alignment, mitotic arrest, and tumor-cell vulnerability. Integrated with recent CTCF findings, it helps translational researchers distinguish kinetochore motor inhibition from broader centromere-architecture defects and design more informative cancer research workflows.

• MLN4924 Workflows for Neddylation Research

  2026-09-28

  MLN4924 gives cancer researchers a time-resolved way to inhibit NAE, connect cullin-RING ligase activity with protein stability, and separate pathway effects from downstream cell-cycle phenotypes. This workflow combines proximal biochemical confirmation with cyclin D3, CDT1, viability, and cell-cycle readouts to investigate trastuzumab resistance and broader tumor-suppression mechanisms.

• LEE011 Succinate: Applied CDK Inhibitor Workflows

  2026-09-28

  Build a mechanism-led workflow for testing CDK4/6 inhibition in breast cancer models, from compound handling to orthogonal cell-cycle readouts. The article also draws a careful, methods-only lesson from an EV71 study without implying that ribociclib has antiviral activity.

• Triptolide in Pancreatitis: A Barrier-First View

  2026-09-27

  Triptolide (PG490) offers a useful way to probe how broad transcriptional disruption intersects with pancreatic barrier injury. This article examines a 2025 acute pancreatitis study, explains the limits of interpreting triptolide as a pathway-specific tool, and translates the findings into practical assay decisions.

• AT13387: Practical Hsp90 Inhibition in Cell Assays

  2026-09-26

  A scenario-based guide to using AT13387 (SKU A4056) in cancer biology research, from stock preparation to interpreting viability and cell-death readouts. It connects reported potency data with practical workflow decisions while distinguishing product evidence from assay-specific recommendations.

• Reversine (A3760): Aurora Kinase Workflow Guide

  2026-09-25

  Reversine (A3760) provides a chemical tool for perturbing Aurora kinase activity in mitotic-regulation and cancer-cell assays. Use it for controlled research experiments—not as a validated cell-line-specific protocol, diagnostic reagent, or medical treatment—and do not treat reported kinase IC50 values as cellular dosing instructions.

• Hoechst 33258 for TNT Tumor Imaging

  2026-09-25

  Use Hoechst 33258 to register nuclei, count cells, and assess DNA content in tumor models studying tunneling nanotubes—without mistaking nuclear fluorescence for KRas transfer or membrane mechanics. This workflow pairs a blue fluorescent DNA stain with confocal imaging and orthogonal controls for more interpretable experiments.

• Aurora A Links SAM Metabolism to Trained Immunity

  2026-09-24

  Li et al. identify Aurora kinase A as a regulator of β-glucan-trained immunity, linking Aurora A inhibition to FOXO3–GNMT activity, reduced S-adenosylmethionine, and weaker inflammatory chromatin marks. The findings connect metabolic control to innate immune memory and show that Aurora A inhibition can also compromise β-glucan-associated tumor growth inhibition in the studied model.

• CENP-E Inhibition as a Probe of Mitotic Fidelity

  2026-09-24

  GSK-923295 offers a precise way to interrogate CENP-E motor function, but chromosome misalignment can arise from more than one centromere defect. By placing direct CENP-E inhibition alongside recent findings on CTCF-dependent centromere maintenance, this article outlines a more discriminating strategy for mitosis and cancer research.

• Gastric Cancer Assembloids Capture Tumor–Stroma Effects

  2026-09-23

  Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids that combine tumor organoids with stromal cell populations obtained from the same tumor. Their findings show that stromal context can alter gene-expression patterns and drug sensitivity, highlighting why tumor-only organoids may not fully represent patient-specific treatment responses.

• PF-573228 FAK Inhibitor Workflow for Cancer Studies

  2026-09-23

  PF-573228 provides a practical way to connect FAK phosphorylation with gastric cancer signaling, cell migration, endothelial behavior, and ferroptosis-related phenotypes. This workflow combines dose-aware pathway validation with orthogonal functional assays and troubleshooting guidance for more defensible mechanism-of-action studies.

• AG-490 and Exosomal SNORD52 in HCC

  2026-09-22

  Explore how AG-490 (Tyrphostin B42) can help test JAK2/STAT6 dependence in exosome-driven hepatocellular carcinoma models. This guide emphasizes causal assay design, pathway selectivity limits, and practical interpretation beyond descriptive signaling studies.

• Rottlerin: PKC Inhibitor Workflows

  2026-09-22

  Rottlerin supports controlled studies of PKCδ-linked signaling, cancer-cell growth, apoptosis, endothelial permeability, and virus entry. This practical guide connects dose selection, time-resolved assays, solvent handling, and orthogonal validation so researchers can distinguish pathway modulation from nonspecific cellular stress.

8020 records 1/535 page Next 12345 下5页 Last page